I'll create a comprehensive submission checklist for your paper "Do Multiple Instance Learning Models Transfer?" but I need to see your manuscript to identify specific risks and missing items.

**Please attach your paper PDF** so I can provide:
- Specific missing sections flagged by line number
- Dataset/license compliance audit
- Ethics statement gaps
- Venue-specific formatting issues

---

## Generic Submission Checklist for "Do Multiple Instance Learning Models Transfer?"

Until you upload the paper, here's a **tailored template** based on your title:

---

## üìã PRE-SUBMISSION CHECKLIST

### SECTION A: Core Content Completeness

#### Required Sections
- [ ] **Abstract** (150-250 words, self-contained)
  - [ ] States the transfer learning question clearly
  - [ ] Mentions source/target domains tested
  - [ ] Quantifies main result (e.g., "X% performance drop when transferring from histopathology to satellite imagery")
  
- [ ] **Introduction**
  - [ ] Motivates why MIL transfer is important
  - [ ] Defines "transfer" operationally (domain shift? task shift? both?)
  - [ ] States research questions explicitly
  
- [ ] **Related Work**
  - [ ] Covers MIL architectures (attention-based, instance-level, embedding-based)
  - [ ] Covers transfer learning theory (domain adaptation, fine-tuning strategies)
  - [ ] Cites key MIL papers: Ilse et al. 2018 (attention MIL), Campanella et al. 2019 (clinical MIL)
  - [ ] Cites transfer learning benchmarks: WILDS, DomainBed
  
- [ ] **Methodology**
  - [ ] Clear definition of source and target domains
  - [ ] Transfer protocol specified (frozen features? fine-tuning? head-only?)
  - [ ] Baseline comparisons (train-from-scratch, ImageNet pretraining)
  - [ ] Statistical significance testing described
  
- [ ] **Experiments**
  - [ ] At least 3 source-target pairs tested
  - [ ] Ablation studies (what transfers: bag aggregation? instance encoder? both?)
  - [ ] Failure case analysis
  
- [ ] **Limitations** (MANDATORY for ACL/NeurIPS/ICLR)
  - [ ] Scope boundaries (e.g., "only vision MIL, not text/graph")
  - [ ] Dataset size constraints
  - [ ] Computational limitations preventing larger-scale study
  
- [ ] **Conclusion**
  - [ ] Summarizes findings
  - [ ] Provides actionable recommendations (when to transfer vs. train from scratch)

---

### SECTION B: Ethics & Compliance (HIGH RISK for MIL papers)

#### Dataset Compliance
- [ ] **Medical imaging datasets** (if used):
  - [ ] IRB approval or exemption statement
  - [ ] HIPAA compliance confirmed
  - [ ] Patient consent documented
  - [ ] De-identification verified
  - [ ] Common datasets: Camelyon16/17 (check license), TCGA (requires dbGaP approval)
  
- [ ] **Satellite/remote sensing** (if used):
  - [ ] Data license allows academic use
  - [ ] Attribution to imagery provider (e.g., Sentinel-2, Landsat)
  
- [ ] **All datasets**:
  - [ ] Table listing: name, license, size, source, citation
  - [ ] Train/val/test splits documented
  - [ ] No test set leakage between source and target domains

#### Compute Disclosure
- [ ] GPU type and quantity (e.g., "8√ó V100, 32GB")
- [ ] Total GPU hours (estimate: pretraining + transfer experiments)
- [ ] CO‚ÇÇ emissions estimate (use [ML CO‚ÇÇ Impact Calculator](https://mlco2.github.io/impact/))
- [ ] Cloud cost or institutional resource acknowledgment

#### Broader Impacts
- [ ] **If medical MIL**: Discussion of clinical deployment risks, false negative/positive rates
- [ ] **If environmental MIL**: Potential misuse for surveillance or resource exploitation
- [ ] Bias evaluation across subgroups (if applicable)

---

### SECTION C: Reproducibility

- [ ] **Code release**:
  - [ ] Anonymous GitHub repo for review (or commitment "upon acceptance")
  - [ ] Requirements.txt / environment.yml
  - [ ] README with setup instructions
  - [ ] Training scripts with hyperparameters
  
- [ ] **Hyperparameters documented**:
  - [ ] Learning rates (source pretraining + target fine-tuning)
  - [ ] Batch sizes (bag-level and instance-level)
  - [ ] Optimizer (Adam/SGD + momentum/weight decay)
  - [ ] Number of epochs, early stopping criteria
  - [ ] Random seeds (report mean ¬± std over 3-5 runs)
  
- [ ] **Model checkpoints**:
  - [ ] Pretrained source models available (or plan to release)
  - [ ] File size and hosting plan (Hugging Face, Zenodo, institutional repo)
  
- [ ] **Evaluation protocol**:
  - [ ] Metrics defined (bag-level accuracy? instance-level AUC? both?)
  - [ ] Statistical tests specified (t-test, Wilcoxon, bootstrap CI)
  - [ ] Significance threshold (p < 0.05)

---

### SECTION D: Formatting & Style

#### Venue-Specific (check your target)

**NeurIPS**
- [ ] 9 pages main content + unlimited references/appendix
- [ ] NeurIPS 2024/2025 LaTeX template (check version)
- [ ] Anonymized (no author names, affiliations, acknowledgments)
- [ ] Line numbers enabled
- [ ] Ethics checklist completed (separate PDF)

**ICML**
- [ ] 8 pages + unlimited references
- [ ] ICML style file (check year)
- [ ] Supplementary material <100MB
- [ ] Anonymized

**ICLR**
- [ ] No strict page limit (8-10 typical)
- [ ] ICLR template
- [ ] OpenReview submission format
- [ ] Reproducibility statement in appendix

**CVPR/ICCV** (if vision-focused)
- [ ] 8 pages + 2 pages references
- [ ] IEEE format
- [ ] Supplementary material guidelines followed

**ACL/EMNLP** (if text MIL)
- [ ] 8 pages + unlimited references
- [ ] Limitations section (unnumbered, before references)
- [ ] Responsible NLP checklist

#### General Formatting
- [ ] All figures have captions and are referenced in text
- [ ] Tables have captions above (not below)
- [ ] No margin overflows or orphaned headers
- [ ] Consistent notation (define symbols in a table if >10 variables)
- [ ] References formatted consistently (use .bib file)
- [ ] Appendix sections labeled (A, B, C...)

---

### SECTION E: Writing Quality

- [ ] Spell-check and grammar-check completed
- [ ] Acronyms defined on first use (MIL = Multiple Instance Learning)
- [ ] No subjective claims without evidence ("clearly", "obviously", "significantly" without stats)
- [ ] Figures readable in grayscale (for printed proceedings)
- [ ] Captions self-contained (reader can understand without reading main text)
- [ ] Related work cites recent papers (2022-2024)

---

## üóìÔ∏è FINAL TIMELINE (6-Week Pre-Submission)

Assuming a **typical conference deadline** (adjust dates to your target):

### Week -6: Content Freeze
- [ ] All experiments completed
- [ ] Results tables finalized
- [ ] Main claims supported by data

### Week -5: First Draft
- [ ] All sections written (rough)
- [ ] Figures/tables placed
- [ ] Internal review by co-authors

### Week -4: Compliance Sprint
- [ ] **Day 1-2**: Dataset license audit ‚Üí create data statement table
- [ ] **Day 3**: Compute disclosure ‚Üí run CO‚ÇÇ calculator, document GPU hours
- [ ] **Day 4**: Ethics statement ‚Üí draft broader impacts, limitations
- [ ] **Day 5**: Reproducibility ‚Üí prepare code repo, write README
- [ ] **Day 6-7**: IRB check (if medical data) ‚Üí obtain exemption letter

### Week -3: Revision & Baselines
- [ ] Address co-author feedback
- [ ] Add missing baselines (if reviewers would ask "why not X?")
- [ ] Strengthen related work section
- [ ] Add ablation studies

### Week -2: Formatting & Polish
- [ ] **Day 1**: Apply venue template, check page limits
- [ ] **Day 2**: Format references, fix citations
- [ ] **Day 3**: Proofread, fix typos
- [ ] **Day 4**: Generate supplementary material PDF
- [ ] **Day 5**: Complete venue checklist (NeurIPS ethics form, etc.)
- [ ] **Day 6-7**: Final co-author approval

### Week -1: Submission Prep
- [ ] **Day 1**: Create anonymous submission (remove author info, acknowledgments)
- [ ] **Day 2**: Upload to submission system, check PDF rendering
- [ ] **Day 3**: Prepare 1-page summary for area chair (if required)
- [ ] **Day 4**: Upload supplementary material (code, data, appendix)
- [ ] **Day 5**: Fill out metadata (keywords, subject areas, conflicts)
- [ ] **Day 6**: Final check of all files
- [ ] **Day 7**: Submit 24 hours before deadline (buffer for technical issues)

### Deadline Day
- [ ] Confirm submission received (check email confirmation)
- [ ] Download submitted PDF for records
- [ ] Celebrate üéâ

---

## ‚ö†Ô∏è RISK ASSESSMENT (Without Seeing Your Paper)

### üî¥ HIGH-RISK (Potential Desk Reject)

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| **Medical data without IRB** | High if using Camelyon, TCGA, or hospital data | Obtain IRB exemption letter NOW; if impossible, switch to public non-medical datasets |
| **Missing limitations section** | Medium (required by most venues) | Add 1-paragraph section before conclusion |
| **No statistical significance** | Medium (MIL has high variance) | Report mean ¬± std over 3+ runs; add t-tests |
| **Undefined "transfer"** | Medium (ambiguous research question) | Clarify: domain shift? task shift? few-shot? zero-shot? |

### üü° MEDIUM-RISK (Reviewer Flags)

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| **Limited domain coverage** | High (hard to test many domains in 6 months) | Acknowledge in limitations; justify domain choices |
| **Missing recent baselines** | Medium (MIL + transfer is active area) | Add comparisons to DSMIL (2021), TransMIL (2021), DTFD-MIL (2022) |
| **Weak theoretical grounding** | Medium (empirical study) | Add analysis: what properties of MIL make transfer hard/easy? |
| **Compute not disclosed** | Low (easy fix) | Add appendix section with GPU hours, CO‚ÇÇ |

### üü¢ LOW-RISK (Polish)

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| **Formatting errors** | Low (template-based) | Use Overleaf or latexdiff for version control |
| **Missing code release** | Low (increasingly expected) | Commit to release upon acceptance |
| **Typos** | Low (proofreading) | Use Grammarly or LanguageTool |

---

## üîç MISSING ITEMS (Likely, Based on Title)

Without seeing your paper, here's what MIL transfer papers **commonly omit**:

### Experiments
- [ ] **Negative transfer analysis**: When does transfer hurt vs. help?
- [ ] **Instance-level vs. bag-level transfer**: Which matters more?
- [ ] **Comparison to ImageNet pretraining**: Is MIL-specific pretraining better?
- [ ] **Data efficiency curves**: How much target data is needed?
- [ ] **Cross-architecture transfer**: Does attention-MIL ‚Üí embedding-MIL work?

### Analysis
- [ ] **Feature visualization**: What do transferred features capture?
- [ ] **Attention map comparison**: Do attention patterns transfer?
- [ ] **Failure modes**: When does transfer completely fail?

### Baselines
- [ ] Train from scratch on target domain
- [ ] ImageNet pretrained encoder + MIL head
- [ ] Domain adaptation methods (DANN, CORAL)
- [ ] Meta-learning approaches (MAML, Prototypical Networks)

### Datasets (if missing)
- [ ] At least 3 source-target pairs from different domains:
  - Medical: Camelyon ‚Üí TCGA
  - Satellite: Functional Map of World ‚Üí BigEarthNet
  - Video: ActivityNet ‚Üí UCF101 (if temporal MIL)

---

## üì§ NEXT STEPS

**Upload your paper PDF** and I'll provide:

1. ‚úÖ **Completed checklist** with ‚úì/‚úó for each item
2. üîß **Specific fixes** with page/line numbers
3. ‚ö†Ô∏è **Risk-ranked issue list** (desk-reject ‚Üí minor)
4. üìã **Venue recommendation** (NeurIPS vs. CVPR vs. ICML based on content)
5. üóìÔ∏è **Personalized timeline** based on nearest deadline
6. üìù **Draft text** for missing ethics/limitations sections

**What I need from you:**
- Paper PDF (current draft, any state)
- Target venue (or top 3 choices)
- Submission deadline date
- Any specific concerns (e.g., "worried about IRB", "not sure about baselines")

I'll turn this around in <5 minutes with concrete, actionable fixes.